Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.

Grab Holdings' revenue growth had declined for six straight quarters from December 2022. Read why I don't recommend GRAB ...

Upstart's Q3 earnings exceeded expectations. Click here to read why I have downgraded UPST stock to sell despite a positive ...

I don't know about you, but I find it both impressive and scary how fast time flies by. The last time I wrote an article ...

Berkshire Hathaway's investment in BNSF is a very good case study for investments in capital-intensive businesses. In ...

Emerson Electric posted strong 2024 results, while guiding for a continuation of solid growth in 2025. Read more about EMR ...

My Hold rating for KDDI Corporation stock is unchanged, following an assessment of the company's recent results and ...

IonQ has shown remarkable stock performance despite being labeled "risky" and "unproven". Find out why I'm bullish on IONQ ...

Urban Edge has delivered over 47% total returns since November 2023, with a current forward yield of 2.89% and a P/FFO ...

Analysts forecast 12.5% to 20.12% net gains from the top-ten Aristocrat Dogs by November 2025. Read more to see my picks.

The market surged after Trump's victory, likely starting a new trending period with strong technicals and favorable ...

Q3 earnings: beat on the bottom line, free cash flow could have been better (a lot better). The big concern, as always, is ...